Hepatocellular carcinoma (HCC) stands as a severe malignant tumor with a profound impact on overall health, often accompanied by an unfavorable prognosis. Despite some advancements in the diagnosis and treatment of this disease, improving the prognosis of HCC remains a formidable challenge. It is noteworthy that lipid metabolism plays a pivotal role in the onset, development, and progression of tumor cells. Existing research indicates the potential application of targeting lipid metabolism in the treatment of HCC. This review aims to thoroughly explore the alterations in lipid metabolism in HCC, offering a detailed account of the potential advantages associated with innovative therapeutic strategies targeting lipid metabolism. Targeting lipid metabolism holds promise for potentially enhancing the prognosis of HCC.
Rationale: Neuroendocrine neoplasms (NENs) originating from neuroendocrine cells occur in the thyroid, respiratory, and digestive systems, with Gallbladder Neuroendocrine Carcinoma (GB-NEC) accounting for only 0.5% of all NENs and 2.1% of gallbladder cancers. Due to its rarity, little is known about GB-NEC’s clinical presentation and treatment. Patient concerns: We report a case of a 52-year-old male presenting with acute upper right abdominal pain, leading to further investigation. Diagnoses: Initial diagnostic workup, including abdominal ultrasound and contrast-enhanced CT, suggested gallbladder malignancy. Post-surgical pathology confirmed GB-NEC, with immunohistochemistry supporting the diagnosis. Interventions: The patient underwent radical cholecystectomy, followed by etoposide plus cisplatin chemotherapy. After disease progression indicated by CT, the patient received additional cycles of chemotherapy with cisplatin and irinotecan, plus targeted therapy with anlotinib and immunotherapy with paimiplimab. Outcomes: The patient showed a partial response to initial treatment. Subsequent liver biopsy confirmed NEC, consistent with small cell carcinoma. With continued treatment, the patient maintains a good survival status. Lessons: GB-NEC is associated with poor prognosis, emphasizing the importance of early detection and multimodal treatment strategies. Our case underlines the potential benefit of a comprehensive treatment plan, including aggressive surgery and chemotherapy, with further research needed to standardize treatment for this rare condition.
The connection between appendiceal disease and cancers of the digestive tract has attracted widespread attention, but conclusion remain controversial. It is still unclear whether appendiceal disease has a definite causal effect on cancer. Our research aims to explore the causal relationship between appendiceal diseases and digestive system tumors. A two-sample Mendelian randomization (MR) analysis was conducted using genome-wide association study datasets to explore the causal impact of appendiceal disease on the risk of cancers. Five different MR methods were used to investigate causality. The stability, heterogeneity, and pleiotropy of MR were also assessed. The presence of appendiceal disease could reduce the incidence of rectal cancer (odds ratio = 0.588, 95% confidence interval: 0.392–0.881, P = .010, by inverse variance weighted method). There was no significant causal effect of appendiceal disease on the risk of other cancers. No horizontal pleiotropy was observed in the MR analysis, and leave-one-out analysis confirmed the stability of the results. The potential causal relationship between appendiceal disease and cancer risk was only observed with rectal cancer in populations of European ancestry. Future work will provide more robust evidence for the connection between appendiceal disease and cancers.